Roche Holding AG

Roche Holding AG is a research healthcare company. It operates through the Roche Pharmaceuticals and Diagnostics segments. The Roche Pharmaceutical division comprises the business segments, such as Roche Pharmaceuticals and Chuga. The Diagnostic division consists of the following four business areas: centralized and point of care solutions, molecular diagnostics, tissue diagnostics and diabetes care. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Spark Therapeutics

The Federal Trade Commission staff reviewing Roche's  plan to buy U.S.-based gene therapy specialist Spark Therapeutics  for $4.3 billion recommended that the deal be approved without requiring any asset sales, the Capitol Forum reported on Thursday.

FTC staff recommends approval of Roche deal for Spark: report

Shares of Seattle Genetics entered the triple-digit club Monday after the biotech company improved upon a breast cancer treatment from Roche. Seattle stock is now in a profit-taking zone.

This Biotech Stock Piggybacked On Roche's Blockbuster — And Succeeded

Johnson & Johnson

Johnson & Johnson’s oncology drugs portfolio is much smaller than that of Roche. However, J&J's oncology drugs sales growth has been faster in the recent years, and this trend is expected to continue in the coming years, while Roche will likely see slower sales growth, as it faces biosimilar.

Here’s How Johnson & Johnson’s Oncology Drugs Portfolio Compares With That of Roche

Roche saw its y-o-y pharma comp accelerate yet again, with 15% growth driven by newer drugs and stronger performance of legacy products.

Roche Delivers Accelerating Growth In The Third Quarter

Roche (RHHBY) reports strong sales in the first nine months of 2019 and raises guidance.

Roche Posts Solid Sales for First 9 Months of '19, Ups View

Swiss drugmaker Roche boosted its full-year guidance on Wednesday and confirmed its $4.8 billion takeover of biotech Spark Therapeutics is on track for year-end. Roche stock slipped.

Roche Boosts Outlook For Third Time In 2019 And Confirms Spark Buyout

Roche (RHHBY) announces positive late-stage data on Rituxan for the treatment of moderate to severe PV.

Roche Announces Positive Late-Stage Data on Rituxan in PV

A member of Swiss drugmaker Roche’s controlling family said on Wednesday that short-term profit maximization has “destroyed the planet” and the world needs a new breed of capitalism putting long-term interests first.

Roche billionaire board member says short-term profit hunger 'destroyed the planet'

Roche (RHHBY) gets FDA approval for Rituxan to treat children with two rare blood vessel disorders. The company also extends the offer period to acquire Spark Therapeutics.

Roche's (RHHBY) Rituxan Receives FDA Nod for Label Expansion

Roche received Breakthrough Therapy Designation status for Gazyva for the treatment of lupus nephritis.

Roche's Advancement Of Kidney Inflammation Drug Could Mark A Newly Available Treatment Option

Roche's (RHHBY) lymphoma drug, Gazyva, obtains Breakthrough Therapy designation in the United States for lupus nephritis.

Roche's Gazyva Now a Breakthrough Therapy for Lupus Nephritis

Roche's (RHHBY) new fixed-dose combination of Perjeta and Herceptin meets the primary endpoint in the phase III study for treating patients with HER2-positive early breast cancer.

Roche's New Perjeta Combo Meets Goal in Breast Cancer Study

Canadian National Railway Company

Diageo

Novo Nordisk

The dividend-growth strategy works for both domestic and foreign markets.

5 High-Quality Dividend Contenders From Overseas To Diversify Your Dividend Growth Portfolio

Roche's (RHHBY) immuno-oncology drug, Tecentriq, meets the primary goal in a late-stage study in NSCLC patients. Also, the company reports positive data on its NMOSD drug in a phase III study.

Roche Reports Positive Data on Tecentriq & NMOSD Drug (Revised)

Roche's (RHHBY) immuno-oncology drug, Tecentriq, meets the primary goal in a late-stage study in NSCLC patients. Also, the company reports positive data on its MS drug in a phase III study.

Roche (RHHBY) Reports Positive Data on Tecentriq & MS Drug

With a third “tissue agnostic” tumor treatment given the green light, oncology is now a genetics-based science

FDA Approval of Roche Cancer Drug Confirms Beginning of New Oncology Era

Swiss drugmaker Roche  sees medicines in its own pipeline driving sales growth over the longer term, Chief Executive Severin Schwan told Reuters on Friday, adding he will not pursue takeovers simply to keep revenue rising.

Roche CEO touts drugs pipeline, rules out M&A just to boost sales

Swiss drugmaker Roche  sees sales rising in the longer term from medicines in its own pipeline, Chief Executive Severin Schwan told Reuters on Friday, adding he does not want or need to do takeovers to mitigate looming patent losses.

Roche doesn't need M&A to boost sales, sees growth from own meds: CEO

The latest EU nod makes Roche's (RHHBY) immuno-oncology drug -- Tecentriq -- the first and only cancer immunotherapy approved for the initial treatment of ES-SCLC in Europe.

Roche's Tecentriq Combo Gets EU Nod for Difficult Lung Cancer

Roche Holding’s (NASDAQ:RHHBY) key blockbuster drugs – Herceptin and Avastin – will lose their market exclusivity in 2019, while another blockbuster drug, Rituxan, has already lost its exclusivity. These three drugs are important for Roche as they generate $21 billion in annual sales, representin.

Is Roche In Trouble With $21 Billion In Sales Nearing Patent Expiry?

Roche's (RHHBY) acquisition of Spark Therapeutics gets delayed once again to allow the FTC more time for review.

Roche Extends Offer to Acquire Spark Therapeutics Yet Again

Abbott Labs

Bristol-Myers

Eli Lilly

Novartis

Cancer-fighting stocks receive a boost from advance research and development. These five stocks can add value to your portfolio.

Five Cancer-Fighting Stocks to Add to Your Portfolio

5 Cancer-Fighting Stocks to Add to Your Portfolio

Roche Holding  and Spark Therapeutics  announced on Tuesday another extension of the Swiss drugmaker's $4.3 billion takeover offer for the U.S. gene therapy specialist as regulatory reviews continue.

Roche, Spark again extend $4.3 billion takeover offer

Roche (RHHBY) wins EU approval for its immuno-oncology drug Tecentriq in combination with Abraxane to treat metastatic triple-negative breast cancer, which is a difficult-to-treat disease.

News for Roche Holding AG Stock (RHHBY)